Several novel FLT3 inhibitors with increased specificity for FLT3 are under study, such as gilteritinib, crenolanib and quizartinib [3], with encouraging results from phase 2 and 3 trials in the relapsed & refractory AML setting [9–11]. Here, FLT3 is linked to acute myeloid leukemia.